89bioETNB
ETNB
About: 89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Employees: 70
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
63% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 40
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
1% less funds holding
Funds holding: 145 [Q2] → 144 (-1) [Q3]
6.37% less ownership
Funds ownership: 105.45% [Q2] → 99.08% (-6.37%) [Q3]
6% less capital invested
Capital invested by funds: $831M [Q2] → $777M (-$54M) [Q3]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]
86% less call options, than puts
Call options by funds: $1.25M | Put options by funds: $9.22M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$29
341%
upside
Avg. target
$36
442%
upside
High target
$49
645%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Ed Arce 42% 1-year accuracy 68 / 161 met price target | 341%upside $29 | Buy Reiterated | 21 Jan 2025 |
Cantor Fitzgerald Kristen Kluska 31% 1-year accuracy 33 / 107 met price target | 341%upside $29 | Overweight Reiterated | 2 Jan 2025 |
Raymond James Steven Seedhouse 13% 1-year accuracy 2 / 16 met price target | 645%upside $49 | Strong Buy Maintained | 8 Nov 2024 |
Financial journalist opinion
Neutral
Seeking Alpha
1 week ago
89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward
89bio, Inc. results from the phase 3 ENTRUST study using pegozafermin for the treatment of patients with Severe Hypertriglyceridemia are expected in the 2nd half of 2025. Prior data from the phase 2 ENTRIGUE study indicated that patients treated with all doses of pegozafermin were able to achieve the primary endpoint with statistical significance. The global severe hypertriglyceridemia treatment market is expected to reach $2.67 billion by 2033.
Negative
Zacks Investment Research
2 weeks ago
New Strong Sell Stocks for January 7th
ETNB, ATUS and ASH have been added to the Zacks Rank #5 (Strong Sell) List on January 7, 2024.
Neutral
GlobeNewsWire
1 month ago
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 48,000 shares of the Company's common stock to one new employee (the “Inducement Grant”) on December 13, 2024 (the “Grant Date”). The Inducement Grant has been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grant was granted as an inducement material to the individual entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
Negative
Zacks Investment Research
1 month ago
New Strong Sell Stocks for November 16th
CLF, ETNB and HZO have been added to the Zacks Rank #5 (Strong Sell) List on November 16, 2024.
Neutral
GlobeNewsWire
1 month ago
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 49,800 shares of the Company's common stock to four new employees (the “Inducement Grants”) on November 25, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
2 months ago
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
New post-hoc analyses reinforce pegozafermin's potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints New post-hoc analyses reinforce pegozafermin's potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints
Neutral
GlobeNewsWire
2 months ago
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing of its previously announced upsized underwritten public offering of 11,455,882 shares of its common stock at a public offering price per share of $8.50 and, in lieu of common stock to a certain investor, pre-funded warrants to purchase up to 3,250,000 shares of its common stock at a public offering price of $8.499. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. In addition, 89bio has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 2,205,882 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds of the offering to 89bio, before deducting the underwriting discounts and commissions and other offering expenses payable by 89bio, are expected to be approximately $125.0 million. The offering is expected to close on or about November 14, 2024, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
2 months ago
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, 89bio is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $15 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities to be sold in the offering are being offered by 89bio.
Neutral
GlobeNewsWire
2 months ago
89bio to Participate in the UBS Global Healthcare Conference
SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024 at 12:30 PM EST and participate in one-on-one investor meetings.
Neutral
GlobeNewsWire
3 months ago
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
SAN FRANCISCO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that new analyses of data from the Phase 2b ENLIVEN trial evaluating pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis will be featured in four poster presentations at the upcoming 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® 2024 being held November 15 to 19, 2024 in San Diego, California.
Charts implemented using Lightweight Charts™